New hope for stage 4 lung cancer? experimental combo enters late-stage trial
NCT ID NCT07365319
First seen Feb 01, 2026 · Last updated May 01, 2026 · Updated 12 times
Summary
This study tests whether adding an experimental drug called EIK1001 to standard immunotherapy (pembrolizumab) and chemotherapy helps people with stage 4 non-small cell lung cancer live longer or slow tumor growth. About 750 adults whose cancer has spread will receive either the new combo or a placebo plus standard treatment. The goal is to see if the new drug improves outcomes without causing severe side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE 4 NSCLC are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.